The NK1 receptor antagonist serlopitant for treatment of chronic pruritus

References

• Millington GWM, Collins A, Lovell CR, et al. British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018. Br J Dermatol. 2018;178:34–60.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Kremer AE, Mettang T, et al. Chronic pruritus in the absence of skin disease: pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2016;17:337–348.
   PubMed Web of Science ®Google Scholar
• Matterne U, Apfelbacher CJ, Vogelgsang L, et al. Incidence and determinants of chronic pruritus: a population-based cohort study. Acta Derm Venereol. 2013;93:532–537.
   PubMed Web of Science ®Google Scholar
• Ständer S, Schafer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221:229–235.
   PubMed Web of Science ®Google Scholar
• Weisshaar E. Epidemiology of itch. Curr Probl Dermatol. 2016;50:5–10.
   PubMedGoogle Scholar
• Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol. 2011;91:674–679.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Sethi M, Rodriguez RV, et al. Retrospective analysis of data from an itch center: integrating validated tools in the electronic health record. J Am Acad Dermatol. 2016;75:842–844.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Apfelbacher C, Jager G, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol. 2006;155:957–964.
   PubMed Web of Science ®Google Scholar
• Sommer F, Hensen P, Bockenholt B, et al. Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol. 2007;87:510–516.
   PubMed Web of Science ®Google Scholar
• Kini SP, DeLong LK, Veledar E, et al. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147:1153–1156.
   PubMedGoogle Scholar
• Ständer S, Zeidler C, Augustin M, et al. S2k Guidelines for the diagnosis and treatment of chronic pruritus - update - short version. J Dtsch Dermatol Ges. 2017;15:860–872.
   Web of Science ®Google Scholar
• Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99:469–506.
   PubMed Web of Science ®Google Scholar
• Saco M, Cohen G. Prurigo nodularis: picking the right treatment. J Fam Pract. 2015;64:221–226.
   PubMed Web of Science ®Google Scholar
• Goon TJA, Yosipovitch G, Chan YH, et al. Clinical characteristics of generalized idiopathic pruritus in patients from a tertiary referral center in Singapore. Int J Dermatol. 2007;46:1023–1026.
   PubMed Web of Science ®Google Scholar
• Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5:e10968.
   PubMed Web of Science ®Google Scholar
• Prignano F, Ricceri F, Pescitelli L, et al. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol. 2009;2:9–13.
   PubMedGoogle Scholar
• Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368:1625–1634.
   PubMed Web of Science ®Google Scholar
• Bautista DM, Wilson SR, Hoon MA. Why we scratch an itch: the molecules, cells and circuits of itch. Nat Neurosci. 2014;17:175–182.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Tominaga M, Takamori K, et al. Roles of glutamate, substance P, and gastrin-releasing peptide as spinal neurotransmitters of histaminergic and nonhistaminergic itch. Pain. 2014;155:80–92.
   PubMed Web of Science ®Google Scholar
• Jeffry J, Kim S, Chen ZF. Itch signaling in the nervous system. Physiology (Bethesda). 2011;26:286–292.
   PubMed Web of Science ®Google Scholar
• Andoh T, Kuraishi Y. Nitric oxide enhances substance P-induced itch-associated responses in mice. Br J Pharmacol. 2003;138:202–208.
   PubMed Web of Science ®Google Scholar
• Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94:265–301.
   PubMed Web of Science ®Google Scholar
• Carstens EE, Carstens MI, Simons CT, et al. Dorsal horn neurons expressing NK-1 receptors mediate scratching in rats. Neuroreport. 2010;21:303–308.
   PubMed Web of Science ®Google Scholar
• Ständer S, Luger TA. NK-1 Antagonists and Itch. Handb Exp Pharmacol. 2015;226:237–255.
   PubMedGoogle Scholar
• Azimi E, Reddy VB, Pereira PJS, et al. Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol. 2017;140:447–53.e3.
   PubMed Web of Science ®Google Scholar
• Azimi E, Reddy VB, Shade KC, et al. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight. 2016;1:e89362.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express neurokinin-1 receptors in chronic itch. Pain. 2015;156:1240–1246.
   PubMed Web of Science ®Google Scholar
• Al-Khater KM, Todd AJ. Collateral projections of neurons in laminae I, III, and IV of rat spinal cord to thalamus, periaqueductal gray matter, and lateral parabrachial area. J Comp Neurol. 2009;515:629–646.
   PubMed Web of Science ®Google Scholar
• Lai JP, Cnaan A, Zhao H, et al. Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions. J Neurosci Methods. 2008;168:127–133.
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Kakigi R. Central mechanisms of itch. Clin Neurophysiol. 2015;126:1650–1660.
   PubMed Web of Science ®Google Scholar
• Haas S, Capellino S, Phan NQ, et al. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci. 2010;58:193–197.
   PubMed Web of Science ®Google Scholar
• Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol. 2018;138:1311–1317.
   PubMed Web of Science ®Google Scholar
• Costantini VJ, Corsi M, Dunstl G, et al. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration. Exp Dermatol. 2015;24:312–314.
   PubMed Web of Science ®Google Scholar
• Trower MK, Fisher A, Upton N, et al. Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour. Exp Dermatol. 2014;23:858–860.
   PubMed Web of Science ®Google Scholar
• Andoh T, Nagasawa T, Satoh M, et al. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 1998;286:1140–1145.
   PubMed Web of Science ®Google Scholar
• Amatya B, Nordlind K, Wahlgren CF. Responses to intradermal injections of substance P in psoriasis patients with pruritus. Skin Pharmacol Physiol. 2010;23:133–138.
   PubMed Web of Science ®Google Scholar
• Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361:1415–1416.
   PubMed Web of Science ®Google Scholar
• Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol. 2010;184:616–622.
   PubMed Web of Science ®Google Scholar
• Data on file. Redwood City, California: Menlo Therapeutics Inc.; 2019.
   Google Scholar
• Pariser DM, Tyring SK, Bagel J, et al. Serlopitant reduced pruritus associated with psoriasis in phase 2 randomized, double-blind, placebo-controlled clinical trial. American Academy of Dermatology Annual Meeting. Washington, D.C; 2019.
   Google Scholar
• Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol. 2018;78:882–91.e10.
   PubMed Web of Science ®Google Scholar
• Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80:1395–1402.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov (NCT02975206). Study of the efficacy, safety, and tolerability of serlopitant for pruritus (itch) in atopic dermatitis (ATOMIK); 2019 [cited 2019 Apr 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02975206?term=serlopitant&rank=5
   Google Scholar
• Chiou A, Choi S, Barriga M, et al. 438 Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in epidermolysis bullosa patients. J Invest Dermatol. 2018;138:S74.
   Web of Science ®Google Scholar
• Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32:1287–1292.
   PubMed Web of Science ®Google Scholar
• Candenas L, Lecci A, Pinto FM, et al. Tachykinins and tachykinin receptors: effects in the genitourinary tract. Life Sci. 2005;76:835–862.
   PubMed Web of Science ®Google Scholar
• Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol. 2006;176:2535–2540, discussion 40
   PubMed Web of Science ®Google Scholar
• Sekizawa K, Jia YX, Ebihara T, et al. Role of substance P in cough. Pulm Pharmacol. 1996;9:323–328.
   PubMedGoogle Scholar